Du är här

2018-08-20

AstraZeneca: AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

New evidence of the persistency of ischaemic risk in post-heart attack
patients, highlighting specific risk factors that may help identify
patients for extended DAPT

Latest data on the links between RAAS inhibitor dose reduction and
increased risk of mortality and MACE in heart failure patients with
hyperkalaemia

First Phase IIa trial results on MEDI6012 in atherosclerosis,
demonstrating cardio-protective potential

AstraZeneca and MedImmune, its global biologics research and
development arm, will present new data from its Cardiovascular, Renal
and Metabolism (CVRM) portfolio of medicines at the European Society
of Cardiology (ESC) Congress in Munich, Germany, 25-29 August 2018,
aiming to help inform clinical practice for the treatment of patients
with overlapping CVRM diseases and multiple risk factors.

Highlights will include:

· New real-world evidence on patients most at risk of future
cardiovascular events, including death, underlining the need for
improved secondary prevention including dual antiplatelet therapy
(DAPT). The latest research also aims to inform clinical practice in
patients with type-2 diabetes treated with glucose-lowering drugs who
may also have coronary artery disease and/or experienced a prior
heart attack or stroke

· Evaluation of real-world consequences in sub-optimal
renal-angiotensin-aldosterone system (RAAS) inhibitor dosing in the
treatment of heart failure patients with hyperkalaemia, aiming to
ensure patients receive optimum cardio-renal protection

· Phase IIa results from the first collaboration between MedImmune
and TIMI Study Group indicate the potential therapeutic benefit of
MEDI6012, a lecithin-cholesterol acyltransferase (LCAT), for the
treatment of atherosclerosis in patients having experienced the most
serious type of heart attack

Ludovic Helfgott, Vice President, Cardiovascular, Renal and Metabolism
at AstraZeneca, said: "At ESC, we continue to explore the intricacies
of cardio-renal and metabolic risk with our determination to improve
patient outcomes. The data to be presented in Munich this year
underscores the persistent ischaemic risk in patients with additional
risk factors such as diabetes or multi-vessel disease, and
demonstrates clinical benefits in heart failure for patients with
hyperkalaemia."

Increased and persistent ischaemic risk in patients with additional
risk factors

· PRECLUDE-2 is an analysis of >100,000 heart attack (myocardial
infarction) patients treated with percutaneous coronary intervention
(PCI) from the SWEDEHEART registry, examining the additive effects of
risk factors (diabetes, renal impairment, age?65yrs, multi-vessel
disease, further heart attacks) on the risk of subsequent ischaemic
events and major bleeding events. [Presentation: #1398. Sunday 26
August, 11:18 - 11:35 CEST at Spotlight Village]

· TIGRIS is a global prospective registry study to evaluate clinical
management, quality of life and outcomes during a two-year follow-up
in high-risk patients with stable coronary artery disease (CAD), one
to three years post-myocardial infarction (MI). [Presentation: #5261.
Tuesday 28 August, 11:52 - 12:05 CEST at Spotlight Village]

· ATHENA is a Swedish nationwide registry study designed to compare
cardiovascular risk in type-2 diabetes patients with any of: a prior
MI or stroke; CAD but without prior MI or stroke; or without CAD,
prior MI or stroke. [Presentation: #P6425. Sunday 26 August, 14:00 -
18:00 CEST at Poster Area]

Maintaining treatment benefit in heart failure patients with
hyperkalaemia

· Results from two real-world studies assessing the impact of RAAS
inhibition in heart failure patients with hyperkalaemia:

o Investigating RAAS inhibitor dosing in heart failure patients including the association between hyperkalaemia and down-titration/discontinuation of RAAS inhibitor therapies. [Presentation: #P1810. Sunday 26 August, 8:30 - 12:30 CEST at Poster Area]

o The association between RAAS inhibitor dosing and the risk of mortality and major adverse cardiovascular events (MACE) in heart failure patients. [Presentation: #P5671. Tuesday 28 August, 8:30 - 12:30 CEST at Poster Area]

Advancing the cardiology pipeline

· Phase IIa results from a trial investigating MEDI6012 recombinant
LCAT in patients with stable atherosclerosis to assess safety and
efficacy; this represents the first findings from a new collaboration
between MedImmune and the TIMI Study Group. [Presentation: #354.
Saturday 25 August, 13:30 - 15:00 CEST at Agora1]

Details of further key abstracts from AstraZeneca/MedImmune: (all
times are CEST)

+-----------------+------------------------------------------------------------+
|Abstract title |Presentation details |
+-----------------+------------------------------------------------------------+
|Multiple |#P823 Saturday 25 August, 11:00 - 16:00 at Poster Area |
|biomarkers and | |
|cause-specific | |
|mortality in | |
|patients with | |
|acute coronary | |
|syndromes - | |
|Insights from the| |
|PLATO biomarker | |
|substudy | |
+-----------------+------------------------------------------------------------+
|Atheroprotective |#P3784 Saturday 25 August, 11:00 - 16:00 at Poster Area |
|effects of | |
|ticagrelor, a | |
|P2Y12 antagonist,| |
|in apolipoprotein| |
|-E-deficient mice| |
+-----------------+------------------------------------------------------------+
|Perceived or |#2227 Sunday 26 August, 14:30 - 14:47 |
|calculated |at Science Box 1 - Poster Area |
|bleeding risk in | |
|patients | |
|undergoing | |
|percutaneous | |
|coronary | |
|intervention: | |
|inside the post | |
|-PCI prospective | |
|registry | |
+-----------------+------------------------------------------------------------+
|Are perceived or |#2228 Sunday 26 August, 14:48 - 15:05 |
|calculated |at Science Box 1 - Poster Area |
|bleeding risk | |
|related to DAPT | |
|choice in | |
|patients | |
|undergoing | |
|percutaneous | |
|coronary | |
|intervention? | |
+-----------------+------------------------------------------------------------+
|Effects of |#P2771 Sunday 26 August, 14:00 - 18:00 |
|ticagrelor vs. |at Poster Area |
|clopidogrel on | |
|neointimal | |
|proliferation in | |
|paclitaxel | |
|-eluting stents | |
|implanted in the | |
|femoropopliteal | |
|district: a | |
|randomized pilot | |
|study using | |
|optical coherence| |
|tomography | |
+-----------------+------------------------------------------------------------+
|Atrial reservoir |#P1710 Sunday 26 August, 8:30 - 12:30 |
|function is |at Poster Area |
|related to | |
|coronary flow | |
|reserve in | |
|patients with | |
|stable coronary | |
|artery disease | |
+-----------------+------------------------------------------------------------+
|Global Leaders |#3224 Sunday 26 August, 12:08 |
|Trial - A |at Main Auditorium |
|randomized | |
|comparison of 24 | |
|month ticagrelor | |
|and 1 month | |
|aspirin versus 12| |
|month dual | |
|antiplatelet | |
|therapy followed | |
|by aspirin | ...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.